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Background: Breast cancer formation is associated with frequent changes in DNA methylation but the extent of
very early alterations in DNA methylation and the biological significance of cancer-associated epigenetic changes
need further elucidation.
Methods: Pyrosequencing was done on bisulfite-treated DNA from formalin-fixed, paraffin-embedded sections
containing invasive tumor and paired samples of histologically normal tissue adjacent to the cancers as well as
control reduction mammoplasty samples from unaffected women. The DNA regions studied were promoters
(BRCA1, CD44, ESR1, GSTM2, GSTP1, MAGEA1, MSI1, NFE2L3, RASSF1A, RUNX3, SIX3 and TFF1), far-upstream regions
(EN1, PAX3, PITX2, and SGK1), introns (APC, EGFR, LHX2, RFX1 and SOX9) and the LINE-1 and satellite 2 DNA repeats.
These choices were based upon previous literature or publicly available DNA methylome profiles. The percent
methylation was averaged across neighboring CpG sites.
Results: Most of the assayed gene regions displayed hypermethylation in cancer vs. adjacent tissue but the TFF1 and
MAGEA1 regions were significantly hypomethylated (p ≤0.001). Importantly, six of the 16 regions examined in a large
collection of patients (105 – 129) and in 15-18 reduction mammoplasty samples were already aberrantly methylated in
adjacent, histologically normal tissue vs. non-cancerous mammoplasty samples (p ≤0.01). In addition, examination of
transcriptome and DNA methylation databases indicated that methylation at three non-promoter regions (far-upstream
EN1 and PITX2 and intronic LHX2) was associated with higher gene expression, unlike the inverse associations between
cancer DNA hypermethylation and cancer-altered gene expression usually reported. These three non-promoter regions
also exhibited normal tissue-specific hypermethylation positively associated with differentiation-related gene expression
(in muscle progenitor cells vs. many other types of normal cells). The importance of considering the exact DNA region
analyzed and the gene structure was further illustrated by bioinformatic analysis of an alternative promoter/intron gene
region for APC.
Conclusions: We confirmed the frequent DNA methylation changes in invasive breast cancer at a variety of genome
locations and found evidence for an extensive field effect in breast cancer. In addition, we illustrate the power of
combining publicly available whole-genome databases with a candidate gene approach to study cancer epigenetics.
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Aberrant DNA methylation is a hallmark of cancer [1]
and may function in various ways to influence transcrip-
tion, as is the case in normal differentiation [2]. Compari-
sons of DNA methylation in cancers to methylation in an
analogous normal tissue or to methylation in a variety of
normal tissues revealed that cancer is very often associated
with a global reduction in DNA methylation [3–5]. Hyper-
methylation of promoter regions overlapping CpG islands
(CpG-rich DNA sequences), most notably in some tumor
suppressor genes, is also a nearly universal feature of
human cancer [6–9].
Because the terms ‘hypermethylation’ and ‘hypomethyla-
tion’ indicate changes relative to some appropriate stand-
ard [10], the choice of normal tissue for comparison is
critical. In cancer patients, otherwise normal-appearing
tissue that is adjacent to the tumor is often used as the
normal control. However, such tissue can contain early
changes in DNA methylation that may contribute to
tumor initiation or may just be markers of the onset of
neoplasia [11, 12]. In the present study, we address the
question of the prevalence of early DNA methylation
changes and field effects (genetic or epigenetic abnormal-
ities in tissues that appear histologically normal) in breast
cancer development using paired adjacent normal and
invasive tissue from a total of 129 patients with breast
cancer together with 18 reduction mammoplasty controls
from cancer-free women. The DNA regions examined for
differential methylation included promoters, far-upstream
regions, and introns as well as DNA repeats. The gene-
associated regions included tumor suppressor genes, stem
cell-associated genes and transcription factor genes. The
regions for analysis were chosen using findings from the
literature and bioinformatics, especially epigenetic data
from the Encyclopedia of DNA Elements (ENCODE) at
the UCSC Genome Browser [13]. We also used bioinfor-
matics to compare our DNA methylation results with
those in The Cancer Genome Atlas (TCGA) [14], one of
the most comprehensive public databases on DNA methy-
lation changes in breast cancer. To elucidate the biological
significance of our findings, we examined whole-genome
expression data for breast cancers from TCGA as well as
DNA epigenetic, chromatin epigenetic and transcriptome
profiles from cell cultures represented at the UCSC Gen-
ome Browser [13, 15]. Our results provide evidence for
frequent field effects in breast cancer development and
illustrate the power of combining whole-genome epige-




Breast cancer patients (N = 129) came from the Breast
Cancer Care in Chicago (BCCC) study and were diagnosedat one of many Chicago area hospitals. The study was ap-
proved by the University of Illinois at Chicago institutional
review board. Women were between the ages of 30 and 79,
self-identified as non-Hispanic White, non-Hispanic Black
or Hispanic, resided in Chicago, had a first primary in situ
or invasive breast cancer diagnosed between 2005 and
2008 and gave written consent to participate in the study
and to allow the research staff to obtain samples of their
breast tumors from diagnosing hospitals. In addition,
18 unaffected, cancer-free patients who underwent a
reduction mammoplasty between 2005-2008 served as
non-cancerous controls. The 18 control tissues were
made available through a standardized protocol involv-
ing an honest broker within the UIC department of
pathology. For all patients, hematoxylin and eosin (H&E)
stained slides from formalin-fixed, paraffin-embedded
(FFPE) tumor blocks were examined to determine repre-
sentative areas of invasive tumor, histologically and mor-
phologically normal-appearing breast tissue adjacent to
the tumor, or confirmed histologically normal tissue ob-
tained from reduction mammoplasty samples (referred to
as control or ‘non-cancerous’ samples). For lumpectomies,
adjacent breast tissue was usually chosen from the same
block as the tumor. However, when available, a separate
block containing breast tissue and no tumor was used as
the non-malignant, adjacent sample. Tissue core samples
were precisely cut from the selected area using a semiau-
tomated tissue arrayer (Beecher Instruments, Inc.).
Because the tissue was fixed and sealed by paraffin, cells
from the invasive tissue could not become dislodged and
contaminate the adjacent tissue or vice versa.
DNA methylation analysis
Dissolution of paraffin was accomplished by the
addition of 1 mL of clearing agent (Histochoice) and in-
cubation at 65 °C for 30 min. Samples were digested by
the addition of 100 μL of digestion buffer consisting of
10 μL 10X Target Retrieval Solution high pH (DAKO,
Glostrup, Denmark), 75 μL of ATL Buffer (Qiagen), and
15 μL of proteinase K (Qiagen) and incubation at 65 °C
overnight. They were then vortexed and checked for
complete digestion. The sample volume was brought
up to ~100 μL, and 20 μL of each sample was treated
with bisulfite and purified using the Zymo EZ-96 DNA
Methylation-Direct™ Kit, with a 15-min denaturation step
at 98 °C followed by a 3.5-h conversion at 64 °C, an add-
itional 15-min denaturation at 98 °C and a 60-min incuba-
tion at 64 °C. DNA was eluted in 40 μL of elution buffer.
Then, PCR was performed with 0.2 μM of each primer, one
of which was biotinylated, and the final PCR product was
purified (Streptavidin Sepharose HP, Amersham Biosci-
ences, Uppsala, Sweden), washed, alkaline-denatured, and
rewashed (Pyrosequencing Vacuum Prep Tool, Qiagen).
Then, pyrosequencing primer (0.5 μM) was annealed to the
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PCR products were sequenced by Pyrosequencing
PSQ96 HS System (Biotage AB) following the manu-
facturer’s instructions. The amplicon regions used are
given in Table 1. The methylation status of each locus
was analyzed individually as a T/C SNP using Pyro-
mark Q96 software (Qiagen, Germantown, Maryland).
Quality control of DNA methylation analysis
All primer-pairs passed tests for sensitivity, reproducibility,
and lack of amplification bias (EpigenDx, Hopkinton, MA).
All reactions had negligible levels of persisting non-CpGTable 1 List of studied gene regions and number of CpGs covered,
Gene/RNA isoforma Test region Test region coordinate
Promoter region
BRCA1 Exon 1 (extended promoter) chr17: 41277463-41277
CD44 Promoter chr11: 35160374-35160
ESR1 Exon 2 (extended promoter) chr6: 152129110 - 152
GSTM2 Promoter chr1: 110210582-11021
GSTP1 Exon 1 (extended promoter) chr11: 67351205-67351
MAGEA1f Promoter chrX: 152486180-1524
MSI1 Promoter chr12: 120807571-1208
NFE2L3 Exon 1 (Extended promoter) chr7: 26192663-261927
RASSF1A Exon 1 (extended promoter) chr3: 50378293-503782
RUNX3 Exon 1 (extended promoter) chr1: 25256198-252563
SIX3 Exon 1 (extended promoter) chr2: 45169609-451695
TFF1 Promoter chr21: 43786664-43786
Upstream of promoter
EN1 Upstream of promoter chr2: 119611385-11961
PAX3g Far upstream chr2: 223170608-22317
PITX2f,h Far upstream or intron I chr4: 111562566-11156
SGK1h Far upstream/ alt. exon 1 chr6: 134638893-13463
Introns
APC Intron 1 or promoter chr5: 112073426-11207
EGFR intron 1 chr7: 55088080-550881
LHX2 Intron 3 chr9: 126777854-12677
RFX1f Intron 7 chr19: 14089984-14089
SOX9 Intron 2 chr17: 70119151-70119
DNA Repeats
LINE-1 N.A. DNA Repeat
Sat2 N.A. DNA Repeat
aWhere there are multiple RefSeq RNA isoforms and expression in HMEC cells by RNA-
HMEC RNA was used in this table to determine the TSS. The isoforms for calculation of
bTSS, transcription start site for the indicated RefSeq isoform. N.A., not applicable
cCGI, CpG island overlapping the test region
dThe number of CpG dinucleotide pairs in the test region (the amplicon used for py
eTSG, Tumor suppressor gene
fAlthough the sequences were in regions that did not make the criteria to be classi
human DNA
gThere is a little expressed, primate specific gene, CCDC140, between PAX3 and the
hThere are distant alternative 5’ ends of these genescytosine residues. For each set of PCR primers, a dilution
series of technical triplicates was examined with ≤15 ng
bisulfite-treated DNA. Primer-pairs were discarded if the
signal for a single nucleotide peak was below 50 relative
light units (RLU’s). The signal to noise (S/N) ratio was cal-
culated by dividing the RLU signal from a single nucleotide
incorporation by the RLU value from a negative control
nucleotide incorporation, and primer-pairs were discarded
if the S/N ratio was less than 10. The reproducibility of
percent methylation was also assessed and primer-pairs
were excluded if the coefficient of variation exceeded 5 %.
The lack of amplification bias was demonstrated for eachBreast Cancer Care in Chicago study (2005-2008)
s (hg19) Distance from TSS (bp)b CGIc # CpGsd TSGe
365 +37 to +135 No 11 Yes
443 -43 to +26 Yes 8 No
129167 +656 to +713 Yes 5 Unclear
0641 -62 to -3 Yes 8 No
215 +139 to +149 Yes 4 Yes
86129 -13 to -64 No 6 No
07474 -588 to -491 No 5
44 +816 to +897 Yes 14 No
33 +74 to +134 Yes 9 Yes
06 +464 to +572 Yes 28 Yes
29 +492 to +572 Yes 12 Unclear
628 -20 to +16 No 5 Unclear
1338 -5579 to -5626 Yes 6 No
0643 -6928 to -6893 Yes 5 No
2677 -18312 to -18413/+602 to +713 No 10 No
8831 -14823 to -14761/+303 to +365 Yes 6 Unclear
3445 +30224 to +30243/-130 to -111 No 4 Yes
04 +1355 to +1379 Yes 4 No
7983 +3966 to +4095 Yes 11 No
969 +27150 to +27165 No 4 No
195 +1990 to +2034 Yes 4 No
N.A. 4 N.A.
N.A. 2 N.A.
seq (ENCODE/Cold Spring Harbor), the RNA isoform closest to the predominant
the distance from the TSS are given in Additional file 1: Tables S1 and S2
rosequencing minus the primer regions)
fied as CGI [13], the regions were rich in CpG compared to the average for
test region whose 5’ end overlaps the 5’ end of PAX3
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human placental DNA (Bioline, Taunton, MA) that had
been methylated (with SssI-methyltransferase) and ampli-
fied DNA left unmethylated (HGHM5 and HGUM5, Epi-
genDx). The empirically determined methylation values
were compared with the known values. An R-square value
of >0.9 was required for validation.
Statistical analysis
Breast Cancer Care in Chicago pyrosequencing study
We conducted pyrosequencing methylation assays on 276
FFPE samples including 258 samples of paired invasive
and adjacent tissue from 129 patients with invasive breast
cancer, as well as 18 reduction mammoplasty non-
cancerous controls. Methylation values were averaged
across multiple neighboring CpG sites to create a single
value for percent methylation for each assay. Mean and
95 % confidence intervals for percent methylation were es-
timated for each gene separately for control mammo-
plasty, adjacent and cancer samples. Differences in means
between unpaired control mammoplasty vs. adjacent and
cancer tissues were evaluated via p-values from independ-
ent Wilcoxin rank-sum tests, whereas differences in
means between paired adjacent and cancer tissues were
evaluated via p-values from dependent Wilcoxon signed-
rank tests. Differences in means between adjacent and
cancer tissues were also estimated in linear regression
with generalized estimating equations to account for the
paired nature of the samples, and 95 % confidence inter-
vals were estimated via 1000 bootstrap replications with
bias correction. These models were adjusted for patient
age, race/ethnicity and tumor characteristics (stage at
diagnosis, tumor grade and either adjusted for or stratified
by ER/PR status). For differential methylation in cancer
vs. adjacent tissue at DNA regions in the complete sample
set, we used a significance level of p ≤ 0.001. For those
DNA regions not pursued beyond the pilot phase, which
were examined in only 37 pairs of cancer and adjacent tis-
sue, we used a significance level of p ≤ 0.01.
The Cancer Genome Atlas (TCGA) bioinformatics study
We examined methylation results for 192 samples of
paired breast cancers and normal tissue (N = 96), based
on TCGA profiles [14] from the Infinium HumanMethy-
lation450 array performed on frozen (not formalin fixed)
samples. Differences in mean methylation between
paired normal and invasive tissues were evaluated using
p-values from dependent Wilcoxon signed-rank tests.
Additionally, to examine the correlation between
regional methylation and gene expression values, inva-
sive breast cancer tumors with both methylation results
and gene expression results (N = 800) were obtained
from TCGA bioportal [16, 17]. Methylation value data
were aquired using the Infinium HumanMethylation450assay and gene expression data were taken as z-scores
using Illumina HighSeq 2000 Total RNA Sequencing
Version 2. Spearman correlation coefficients were calcu-
lated to measure the association between regional loci
methylation level and gene expression level. The level
for significance for both of the previously identified ana-
lyses was defined as p ≤ 0.01. Lastly, other whole-
genome databases that are part of the ENCODE project
[18, 19] and publicly available profiles for all mappable
CpGs in control and cancer-derived breast epithelial cell
cultures using next-generation sequencing of bisulfite-
treated DNA (bisulfite-seq) [15] were examined for
DNA methylation, transcription, or histone modification
as described in Results.
Results
Choice of regions for analysis
We chose a diverse set of genes and two DNA repeats
(Table 1) to assay for DNA methylation in cancer, adja-
cent and control mammoplasty tissues. Eight of the 23
examined DNA regions overlapped or were near regions
previously reported to be hypermethylated in breast can-
cer vs. non-cancerous breast tissue, namely, EGFR [20],
GSTP1 [21], LHX2 [22], PITX2 [23], RASSF1A [24],
RUNX3 [25], APC [26] and BRCA1 [27, 28] or hypo-
methylated in breast cancer vs. normal breast, namely,
TFF1 [29], satellite 2 and LINE-1, DNA repeats [30, 31].
In addition, the first six of the above-mentioned gene
regions displayed hypermethylation in one or two breast
cancer cell lines (MCF-7 and T-47D) relative to a human
breast epithelial cell culture derived from normal breast
tissue (human mammary epithelial cells, HMEC) and
compared with most normal tissues, including breast tis-
sue as seen in whole-genome DNA methylation data
(reduced representation bisulfite sequencing, RRBS)
from the ENCODE project [5, 13, 19]. An additional
seven gene regions (EN1, PAX3, SIX3, SOX9, RFX1,
SGK1 and NFE2L3) were chosen mostly on the basis of
hypermethylation profiled by RRBS in breast cancer cells
lines (and often other cancer cell lines) vs. the above-
mentioned normal cell cultures or tissues [13]. The first
five of these genes also had been previously reported to
display hypermethylation in non-breast neoplasms vs.
control tissue [32–35].
Figure 1 illustrates ENCODE data at the UCSC Gen-
ome Browser [13] for the studied region far upstream of
EN1, one of the gene regions chosen for examination in
this study on the basis of RRBS DNA methylation data
for breast cancer cell lines vs. control cells and tissues.
EN1 encodes a homeobox-containing transcription fac-
tor that is implicated in the development of the nervous
system and serves as a marker of certain neurons [36].
Underneath the diagrammed gene structure (Panel a)




Fig. 1 Example of how some gene regions were chosen for examination in this study on the basis of available RRBS DNA methylation profiles for
breast cancer cell lines and normal cell cultures and tissues visualized in the UCSC Genome Browser [13]. a The EN1 gene structure with exons as
heavy horizontal bars; b, the aligned CpG islands in the illustrated region.; c, DNA methylation (ENCODE/RRBS/HudsonAlpha) profiles for the
indicated cell cultures and normal tissues using an 11-color, semi-continuous scale (see color key) to indicate the average DNA methylation levels
at each monitored CpG site; d, aligned transcription results indicating that the non-transformed breast cancer cell line is not transcribing this gene
irrespective of its lack of DNA methylation. Paradoxically, normal myoblasts are transcribing it despite some upstream DNA methylation. All data
are from ENCODE [19]
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tion status quantified at the RRBS-detected CpGs in a
variety of cell cultures and normal tissues using an 11-
color, semi-continuous scale (see color key) to indicate
the average DNA methylation levels at each monitored
CpG site (ENCODE/RRBS/HudsonAlpha Institute, [13]).
The MCF-7 breast cancer cell line and several diverse
cancer cell lines were hypermethylated throughout most
of the gene and its upstream region relative to HMEC,
normal breast tissue, other normal tissues and the
majority of non-cancer cell cultures (Panel c and data
not shown from ENCODE [13]). The exceptions were
normal muscle cell cultures (myoblasts and myotubes)
but these were methylated in a smaller region that did
not overlap the beginning of the gene as did the hyper-
methylation in MCF-7 cells. T-47D, the secondexamined breast cancer cell line in this RRBS database,
was hypermethylated relative to HMEC but to a lesser
extent than for MCF-7 cells.
We also examined two gene regions (ESR1 and
GSTM2) found to display hypermethylation preferen-
tially in more aggressive breast cancers [37, 38]. In
addition, we studied CD44 and MSI1, which have been
reported to have promoter hypomethylation in triple-
negative breast cancers, that is, cancers that lack estro-
gen receptors (ER), progesterone receptors (PR), and
human epidermal growth factor-2 receptors (HER2)
[39]. The last gene region we examined was MAGEA1,
which encodes a cancer-testis antigen that is not
expressed in normal somatic tissues but is sometimes
expressed in breast cancer [40]. Cancer-testis antigen
genes are often hypomethylated in various kinds of
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in breast cancer was not known.
Samples and method used for DNA methylation analysis
The breast tissue samples analyzed for DNA methylation
were invasive cancer (referred to as “cancer”), histologi-
cally normal tissue adjacent to the cancer (referred to as
“adjacent tissue”) and non-cancerous reduction mammo-
plasty samples (referred to as “control mammoplasty”).
Characteristics of the 129 breast cancer patients and
their tumors are listed in Table 2. The carcinomas were
equally likely to be stage I vs. later stages, equally dis-
tributed across histological grades, and one third of
them lacked both estrogen and progesterone receptors.
Before studying the full sample set, we conducted a pilot
study on the 23 test regions using paired samples of can-
cer and adjacent tissue from 37 patients, and on samples
from 18 reduction mammoplasty patients. Of the 23 test
regions, 16 were analyzed in an additional set of 92
patients with paired cancer and adjacent tissue samples
to give a total of 276 samples.
Methylation analysis was performed by pyrosequenc-
ing of bisulfite-treated DNA. This method allowed us to
monitor individual reactions for incomplete bisulfite
modification and to check for PCR-bias [42, 43]. We
used FFPE-derived DNA, which is partly degraded and
difficult to analyze because of crosslinking resulting fromTable 2 Characteristics of the 129 breast cancer patients with
adjacent normal and/or invasive samples, Breast Cancer Care in
Chicago study (2005-2008)







non-Hispanic White 42 33
non-Hispanic Black 57 44
Hispanic 30 23
Stage at Diagnosis
Stage I 60 47






One or both positive 82 67
Double negative 40 33the formalin fixation process [44], and which may be
available in only small amounts. These problems are
compounded by further degradation associated with
bisulfite treatment for the methylation analysis. Bisulfite-
based pyrosequencing overcomes these problems and
provides accurate quantification [43].
Variation in DNA methylation among samples of the
same tissue type
As expected for cancer-linked DNA methylation
changes [7], there was large variability in the average 5-
methylcytosine (5mC) content at a given test region
among individual cancer samples, as seen in the high
standard deviation (SD) relative to the mean methyla-
tion values (Table 3). The between-sample variability
contrasted with the much lower within-sample variabil-
ity of technical duplicates (data not shown), observed
in the pilot study. Moreover, the control mammoplasty
samples generally showed less variability in average
5mC content compared with adjacent or cancer sam-
ples (Table 3).
DNA hypermethylation in cancer vs. adjacent and control
mammoplasty samples
Figure 2 (Panel a) displays the mean percent methylation
and 95 % confidence limits for each of the 23 studied
DNA regions and shows the results separately for con-
trol mammoplasty, adjacent and cancer samples. Hyper-
methylation in cancer vs. adjacent samples was seen at a
significance level of p ≤ 0.001 for 12 of the 16 test re-
gions in the large-scale study and at a significance level
of p ≤ 0.01 for three of the seven regions not pursued
beyond the pilot phase (Table 3). Twelve of the regions
were also significantly hypermethylated in cancer vs.
control mammoplasty samples (p ≤ 0.01) (Table 3). The
difference in the average percent methylation for signifi-
ciantly hypermethylated sequences in cancer vs. adjacent
tissue or for cancer vs. control mammoplasty tissue was
largest for RASSF1A (23.6 and 30.5, respectively).
Cancer-associated hypermethylation was seen in test
sequences that were in extended promoter regions
(regions immediately upstream or downstream of the
transcription start site, TSS), in sequences upstream of
promoter regions and in introns. A mostly similar pat-
tern of cancer hypermethylation of these gene regions
was observed in TCGA for breast cancer and paired nor-
mal samples (Fig. 2, panel b).
Eight of the ten test regions overlapping DNA se-
quences previously reported to be hypermethylated in
breast cancer vs. nonmalignant breast tissue or in more
aggressive vs. less aggressive cancer types (APC , EGFR,
GSTM2, GSTP1, LHX2, PITX2, RASSF1A and RUNX3)
exhibited hypermethylation in this study at the desig-
nated p-value cutoff levels (p < 0.001 and p < 0.01,
Table 3 Mean percent methylation by gene and tissue type from the Breast Cancer Care in Chicago study
DNA region Controla Adjacentb Invasivec Adjacent vs. control Invasive vs. control Invasive vs. adjacent
N Mean SD N Mean SD N Mean SD Diff. P-valued Diff. P-valued Diff. P-valuee
Promoter region
BRCA1 15 1.6 1.1 105 1.4 4.3 105 3.0 9.6 -0.2 NS 1.4 NS 1.6 0.031
CD44f 18 1.6 0.6 37 1.8 0.9 37 2.6 2.7 0.2 NS 1.0 NS 0.8 NS
ESR1f 18 5.9 3.1 37 7.9 6.0 37 6.7 7.8 2.0 NS 0.8 NS -1.2 NS
GSTM2 16 1.8 2.0 107 3.0 6.1 107 19.3 22.9 1.2 NS 17.5 0.004 16.3 <0.0001
GSTP1 17 2.5 2.0 118 1.6 3.7 118 9.9 16.8 -0.9 NS 7.4 NS 8.3 <0.0001
MAGEA1f 17 84.8 4.9 32 84.2 4.8 37 67.0 16.2 -0.6 NS -17.8 0.0001 -17.2 <0.0001
MSI1f 18 3.8 2.1 36 4.2 2.5 37 9.2 7.4 0.4 NS 5.3 0.0001 5.0 0.0003
NFE2L3f 17 28.9 14.7 36 26.9 13.7 37 33.7 24.4 -2.0 NS 4.8 NS 6.8 NS
RASSF1A 18 2.8 2.2 124 9.7 10.7 124 33.3 23.4 6.9 <0.0001 30.5 <0.0001 23.6 <0.0001
RUNX3 17 3.3 1.2 119 4.0 3.3 119 11.4 12.7 0.7 NS 8.1 0.061 7.4 <0.0001
SIX3 17 5.8 2.8 115 5.3 4.0 115 15.7 14.9 -0.5 NS 9.9 0.026 10.4 <0.0001
TFF1 18 81.8 5.4 122 72.0 16.9 122 49.2 22.3 -9.8 0.008 -32.6 <0.0001 -22.8 <0.0001
Upstream of promoter
EN1 18 17.8 5.3 122 20.0 10.2 122 32.9 15.3 2.2 NS 15.1 <0.0001 12.9 <0.0001
PAX3 17 2.9 1.2 121 4.0 5.2 121 10.8 11.1 1.1 NS 7.9 0.0003 6.8 <0.0001
PITX2f 17 26.5 6.1 35 27.6 8.6 36 36.1 11.3 1.1 NS 9.6 0.001 8.5 <0.0001
SGK1 18 1.6 1.2 124 3.9 3.7 124 13.0 12.2 2.3 <0.0001 11.4 <0.0001 9.1 <0.0001
Introns
APC 18 2.0 1.9 114 2.9 8.3 114 14.8 19.6 0.9 NS 12.8 0.058 11.9 <0.0001
EGFR 18 4.5 1.3 126 7.3 5.2 126 19.4 14.8 2.8 0.006 14.9 <0.0001 12.1 <0.0001
LHX2f 18 21.1 5.3 36 25.8 13.1 37 36.1 12.6 4.7 NS 15.0 <0.0001 10.3 0.0007
RFX1 18 18.0 5.3 126 19.3 9.7 126 39.4 13.1 1.3 NS 21.4 <0.0001 20.1 <0.0001
SOX9 18 8.4 4.3 123 9.1 7.4 123 15.2 14.3 0.7 NS 6.8 NS 6.1 0.002
DNA Repeats
LINE-1 18 68.7 1.4 129 72.8 2.6 129 71.2 4.3 4.1 <0.0001 2.5 0.0003 -1.6 0.001
Sat2 18 52.6 8.0 128 57.4 12.7 128 52.0 13.4 4.8 0.002 -0.6 NS -5.4 <0.0001
aReduction mammoplasty samples from women unaffected with breast cancer
bSamples from histologically normal tissue adjacent to the tumor
cSamples from the cancer component of the tumor
dFrom an independent sample Wilcoxon Rank Sum test comparing control mammoplasty vs. adjacent samples
eFrom a dependent sample Wilcoxon Sign Rank test. P-values > 0.10 are suppressed. Diff, difference in mean methylation; SD, standard deviation
fThese seven assays were not pursued beyond the pilot phase and, therefore, had 32-37 paired cancer and adjacent samples instead of 105-129
Differences were determined to be statistically significant at p < 0.001 for the complete sample set and p < 0.01 for regions only examined in the pilot study
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very small changes in the extent of methylation (<2 % dif-
ferential for cancer vs. adjacent tissue). BRCA1 methyla-
tion was low for all three tissue types, ranging from a
mean of 1 % in adjacent to only 3 % in cancer samples.
However, BRCA1 showed the largest relative SD of all
tested regions (>3-fold, Table 3). Four percent of cancer
samples and none of the adjacent or control mammo-
plasty samples displayed BRCA1 methylation in excess of
20 % (results not shown). For additional DNA regions that
were hypermethylated in breast cancer cell lines or in can-
cers other than breast (EN1, NFE2L3, PAX3, RFX1, SGK1,SIX3 and SOX9), significant hypermethylation was seen in
the cancer tissue compared with adjacent tissue with the
exceptions of SOX9 (p = 0.002) and NFE2L3 (Table 3).
Results were not substantively different after adjusting
for patient and tumor characteristics (age, race/ethnicity,
ER/PR status, stage and grade) (Table 4). When stratify-
ing estimates by ER/PR status, several genes appeared to
display differential changes in methylation for adjacent
vs. cancer tissues (Table 4). GSTM2 exhibited more
hypermethylation for ER/PR negative tumors (p < 0.05),
whereas EGFR displayed greater hypermethylation for
ER/PR positive tumors (p < 0.05). TFF1 and MAGEA1
Fig. 2 Mean percent methylation and 95 % error bars by gene and tissue type for the DNA regions listed in Table 1. a DNA methylation analysis
of samples from the Breast Cancer Care in Chicago study (2005-2008) as determined by our bisulfite pyrosequencing. Control samples (reduction
mammoplasty) from unaffected women are represented by green bars, cancer-adjacent, histologically normal samples by blue bars and cancer
samples by red bars. b Bioinformatic analysis of DNA methylation of breast cancer samples and paired non-cancerous adjacent samples from The
Cancer Genome Atlas (TCGA). Paired non-cancerous adjacent samples are represented by blue bars and cancer samples by red bars. In both
panels, promoter sequences are displayed first, followed by upstream sequences, then introns and lastly, DNA repeats
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mors. NFE2L3 displayed hypermethylation for ER posi-
tive tumors and hypomethylation for ER negative
tumors (p < 0.05) (Table 4).DNA hypomethylation in cancer vs. adjacent and control
mammoplasty samples
We found that the promoter regions of TFF1 and
MAGEA1 were hypomethylated in cancer compared
Table 4 Adjusted differences in mean % methylation comparing adjacent (referent) to cancer tissue, overall and stratified by ER/PR
status
All samples ER/PR Positive ER/PR Negative
Na Diff.b 95 % CIc P-Valued Na Diff.b 95 % CIc P-Valued Na Diff.b 95 % CIc P-Valued
Promoter regions
BRCA1 198 1.7 (0, 4) NS 136 1 (-1, 4) NS 62 3 (0, 8) 0.09
CD44e 54 0.5 (0, 1) NS 32 0 (-0.4, 1) NS 22 0 (0,2) NS
ESR1e 54 -1.5 (-3, 0) 0.099 32 -1 (-4, 1) NS 22 -2 (-4, 1) NS
GSTM2 212 16.8 (13, 21) < 0.0001 146 10 (6, 16) < 0.0001 66 32 (24, 38) < 0.0001
GSTP1 227 8.3 (6, 12) < 0.0001 159 9 (6, 14) < 0.0001 68 6 (2, 12) 0.016
MAGEA1e 54 -14.5 (-22, -9) < 0.0001 32 -22 (-30, -14) < 0.0001 22 -4 (-12, 3) NS
MSI1e 54 4.7 (2, 8) 0.005 32 4 (1, 10) 0.057 22 5 (1, 9) 0.01
NFE2L3e 54 5.6 (-4, 16) NS 32 19 (9, 31) 0.001 22 -15 (-26, -4) 0.01
RASSF1A 234 23.5 (19, 28) < 0.0001 160 26 (21, 31) < 0.0001 74 18 (12, 25) < 0.0001
RUNX3 227 6.6 (4, 9) < 0.0001 156 9 (6, 11) < 0.0001 71 2 (-1, 7) NS
SIX3 221 10.9 (9, 14) < 0.0001 151 10 (7, 14) < 0.0001 70 13 (8, 19) < 0.0001
TFF1 230 -21.6 (-26, -17) < 0.0001 159 -25 (-30, -19) < 0.0001 71 -14 (-23, -5) 0.002
Upstream of promoter
EN1 230 13.1 (10, 17) < 0.0001 158 12 (8, 16) < 0.0001 72 16 (9, 24) < 0.0001
PAX3 230 7.3 (5, 10) < 0.0001 159 6 (4, 9) < 0.0001 71 10 (6, 15) < 0.0001
PITX2e 54 7.8 (4, 11) < 0.0001 32 7 (3, 10) < 0.0001 22 10 (1, 16) 0.026
SGK1 233 9.8 (8, 12) < 0.0001 160 9 (7, 12) < 0.0001 73 11 (7, 16) < 0.0001
Introns
APC 221 12.3 (9, 16) < 0.0001 153 12 (8, 16) < 0.0001 68 15 (9, 22) < 0.0001
EGFR 235 12 (9, 15) < 0.0001 161 15 (11, 18) < 0.0001 74 6 (2, 11) 0.009
LHX2e 54 8.1 (2, 15) 0.017 32 8 (3, 13) 0.006 22 9 (-5, 22) NS
RFX1 235 19.8 (17, 23) < 0.0001 161 20 (16, 23) < 0.0001 74 21 (16, 26) < 0.0001
SOX9 231 6.2 (3, 9) < 0.0001 158 6 (3, 10) < 0.0001 73 6 (1, 13) 0.031
DNA Repeats
LINE-1 238 -1.5 (-2, -1) < 0.0001 162 -2 (-3, -1) < 0.0001 76 -1 (-3, 0) 0.074
Sat2 237 -5.4 (-9, -2) 0.001 161 -6 (-10, -2) 0.003 76 -5 (-10, 1) 0.109
aNumber of samples analyzed; the small differences in numbers of samples in this table compared to Table 3 are due to missing data on ER/PR status
bDifference in mean percent methylation (cancer and adjacent) was estimated via linear regression model with generalized estimating equations to account for
within-patient covariance
cBias corrected, bootstrapped 95 % confidence intervals (CI) were estimated via 1000 bootstrap replications to account for skewed methylation distributions
dApproximate p-value estimated from a Wald test of the normal-based bootstrapped estimate over its standard error. P-values > 0.1 are suppressed
eThese seven assays were not pursued beyond the pilot phase and therefore have considerably fewer cancer and adjacent tissue samples analyzed
All estimates of mean percent methylation are adjusted for age, race/ethnicity, stage at diagnosis, tumor grade, and either adjusted for or stratified by
ER/PR status
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mammoplasty samples (p < 10-4; Tables 3 and 4).
MAGEA1 had high mean methylation levels in the control
mammoplasty samples and adjacent samples (>80 % for
both) but much lower DNA methylation levels in the
cancer samples. TFF1 also had high mean methylation
levels in the control mammoplasty tissue (82 %), al-
though methylation levels were lower in adjacent tissue
(72 %), and lowest in cancer tissue (49 %). Cancer-
associated hypomethylation of TFF1 and MAGEA1
was also observed by Illumina HumanMethylation450analysis of DNA methylation in the TCGA database for
breast cancer and paired normal samples (Fig. 2b,
Panel b and Table 5). In addition, pyrosequencing re-
vealed that the two studied DNA repeats, the tandem,
juxtacentromeric satellite 2 (Sat2) and interspersed
repeat LINE-1, displayed significant hypomethylation
in cancer vs. adjacent samples (Table 3). However, the
extent of hypomethylation for these highly repeated
sequences was much less (5.4 and 1.6 %, respectively),
which is not surprising given the very high copy num-
ber for these repeats.




TCGA database, within study region +/- 100 bp TCGA database, within study region
Pyroseqa Illum. 450 k: Mean % methylation Assn. with
expr.
Illum. 450 k: Mean % Methylation Assn. with
expr.








Diffd P-valuee ρf P-value
Promoter region
BRCA1 11 13 4 4 0 NS -0.19 0.0000 9 3 4 0 NS -0.20 0.0000
CD44 8 5 4 9 5 0.0001 -0.18 0.0000 1 6 10 5 0.004 -0.18 0.0000
ESR1 5 2 67 40 -28 0.0000 -0.52 0.0000 2 67 40 -28 0.0000 -0.52 0.0000
GSTM2 8 3 4 16 13 0.0000 -0.13 0.0003 1 2 2 -1 0.0000 -0.13 0.0002
GSTP1 4 2 7 24 17 0.0000 -0.43 0.0000 0 — — — — —
MAGEA1
6 2 97 77 -21 0.0000 -0.23 0.0000 2 97 77 -20 0.0000 -0.23 0.0000
MSI1 5 2 3 6 3 0.0000 -0.20 0.0000 0 — — — — —
NFE2L3
14 1 39 48 9 0.0001 -0.55 0.0000 0 — — — — —
RASSF1
9 2 12 47 35 0.0000 -0.18 0.0000 1 9 49 41 0.0000 -0.16 0.0000
RUNX3 28 1 2 23 21 0.0000 -0.28 0.0000 0 — — — — —
SIX3 12 4 6 24 18 0.0000 -0.21 0.0000 2 4 26 22 0.0000 -0.20 0.0000
TFF1 5 4 77 46 -31 0.0000 -0.20 0.0000 1 74 47 -27 0.0000 -0.19 0.0000
Upstream of promoter
EN1g 6 2 23 32 8 0.0000 0.12 0.001 0 — — — — —
PAX3 5 2 6 30 24 0.0000 -0.12 0.004 1 9 29 19 0.0000 -0.10 0.003
PITX2g 10 2 23 38 15 0.0000 0.22 0.0000 0 — — — — —
SGK1 6 4 9 21 12 0.0000 -0.10 0.003 2 5 17 12 0.0000 -0.11 0.003
Introns
APCg 4 11 6 28 22 0.0000 0.13 0.002 3 5 28 23 0.0000 0.12 0.004
EGFR 4 1 9 37 29 0.0000 -0.15 0.0000 1 9 37 29 0.0000 -0.15 0.0000
LHX2g 11 1 17 32 15 0.0000 0.24 0.0000 0 — — — — —
RFX1 4 0 — — — — — 0 — — — — —
SOX9 4 1 5 15 11 0.0000 -0.34 0.0000 0 — — —
aPyrosequencing (Pyroseq) assay coordinates are given in Table 1
bNon-cancer tissue adjacent to paired breast cancer from 96 patients in the TCGA Illumina Methylation450 database for genome-wide DNA methylation [14]
cSamples from the invasive component of the breast cancer from patients in the TCGA Methylation450 and expression (expr.; RNA-seq) databases [16, 17]
dDifference in mean % methylation for cancer minus that for the paired adjacent tissue for the 96 patients with both in the TCGA database
eFrom a dependent sample Wilcoxon Sign Rank test; P-values > 0.10 are suppressed
fSpearman correlation coefficient for methylation levels vs expression levels among all the invasive breast cancer samples in the TCGA database
gThe four underlined genes were the only ones that had a positive association of cancer methylation in non-promoter regions with expression levels of the
associated gene
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vs. control mammoplasty samples
A comparison that could be made with our pyrose-
quencing data, that is not available in the TCGA data-
base for breast samples, is an analysis of cancer-adjacent
tissue vs. breast tissue from cancer-free individuals.
Comparing methylation levels of the adjacent samples in
breast cancer patients and the control mammoplastysamples revealed that RASSF1A had the largest differ-
ence in mean methylation (Table 3). Only five other se-
quences displayed hypermethylation or hypomethylation
in adjacent vs. control mammoplasty samples at the sig-
nificance level of p < 0.01 (SGK1, LINE-1, EGFR, Sat2
and TFF1; Table 3) and only the first two of these at p ≤
0.001. Surprisingly, the most statistically significant dif-
ference between methylation in adjacent tissue relative
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LINE-1 (p < 10-9) as contrasted with the hypomethylation
of this repeat in cancer vs. adjacent samples (p = 10-4).
However, the magnitude of the expected [45] hypomethy-
lation of LINE-1 repeats in cancer vs. adjacent tissue was
small (-1.6 percentage points) and the magnitude of
observed hypermethylation was modest (+4.1 percentage
points). Mammoplasty control samples came from women
who were younger (mean of 33 y, range 16-68) than the
patients from whom the breast cancer samples originated
(mean of 56 y, range 25-77), as would be expected given
the availability of such samples. In addition, there are
some differences in the cellular composition of breast tis-
sue dependent upon whether it was derived from obese
women, the likely source of most mammoplasty samples
[46]. Therefore, the small differences in methylation, as
seen for LINE-1, need to be interpreted with caution.
Correlations between cancer-associated changes in DNA
methylation and gene expression
An analysis of the Illumina HumanMethylation450
DNA methylation database for invasive breast cancers
and the RNA-seq expression database for the same can-
cers in the TCGA collection [14] demonstrated that the
methylation status of most of the studied regions was
significantly associated with altered expression of the
corresponding gene (Table 5). For this analysis, we
focused on either the same small region studied by
pyrosequencing in this study or that region extended by
100 bp on either side (Table 5). All the promoter
regions for which we demonstrated cancer-linked
hypermethylation by pyrosequencing (BRCA1, CD44,
GSTM2, GSTP1, MSI1, NFE2L3, RASSF1, RUNX3 and
SIX3) exhibited an inverse correlation with expression
among the cancers. Therefore, as expected [47], more
promoter methylation was associated with lower ex-
pression levels. The two promoter regions displaying
cancer hypomethylation (TFF1 and MAGEA1) also dis-
played an inverse correlation between methylation
among cancers and expression indicating that cancer-
linked losses in promoter methylation were associated
with increased (and abnormal) expression. Importantly,
the only regions that displayed a positive correlation
between methylation and expression among the breast
cancers in the TCGA database were four far-upstream
or intragenic regions for the genes EN1, PITX2, APC
and LHX2.
Insights into DNA hypermethylation positively associated
with gene expression from the ENCODE database
We compared DNA methylation from ENCODE RRBS
profiles of normal breast epithelial cells (HMEC) and
several breast cancer cell lines, MCF-7 and T-47D
(ENCODE/RRBS/HudsonAlpha Institute; [18, 19]). Inaddition, profiling of all mappable CpG sites in HMEC
and the breast cancer cell line HCC1954 was available
[15, 18]. As expected, differences in DNA methylation
between promoter regions that we examined by pyro-
sequencing mostly mimicked the hypermethylation or
hypomethylation observed in cancer vs. adjacent tissue
or control mammoplasty tissue analyses by pyrose-
quencing (Additional file 1: Table S1).
Next we used ENCODE data to analyze transcriptome
profiles available for HMEC, many other normal cell cul-
tures and MCF-7 in the ENCODE database (ENCODE/
RNA-seq/Cold Spring Harbor Lab) to elucidate the posi-
tive association shown in Table 5 between cancer DNA
hypermethylation and gene expression for the pyrose-
quenced regions in EN1, LHX2, PITX2 and APC. With
respect to EN1, methylation of its far-upstream region
was positively associated with expression in a compari-
son of normal cell cultures. Normal myoblast and myo-
tube cultures, which strongly and preferentially express
EN1 were significantly hypermethylated in this far-
upstream region when compared with other studied cell
cultures and tissues [48] including HMEC and MCF-7
cells (Fig. 1c and d). Unlike myoblasts and myotubes,
the MCF-7 breast cancer cell line was hypermethylated
not only in this region but throughout the body of the
EN1 gene, which may explain why MCF-7 cells did not
express EN1 while myoblasts and myotubes did. Similar
to the studied EN1 far-upstream region, intron 3 of
LHX2 and intron 1 of PITX2, exhibited muscle lineage
hypermethylation directly associated with highly specific
expression in myoblasts (data not shown, [18]). In con-
trast, APC is broadly expressed among diverse cell types.
Histone modifications and gene expression from ENCODE
We also examined the pyrosequenced regions in EN-
CODE histone modification profiles, which were avail-
able for HMEC but not for MCF-7 (ENCODE/Histone
Modifications by ChIP-seq/Broad Institute). As ex-
pected, promoter hypermethylation in cancer was usually
in regions displaying active promoter-type histone modifi-
cations in HMEC (Additional file 1: Table S1). These his-
tone modification profiles distinguish between chromatin
regions that are predicted to be active promoters (histone
H3 lysine-4 trimethylation, H3K4me3, and H3K27 acetyl-
ation, H3K27ac), silenced regions (H3K27me3), active
enhancers (H3K4me1 and H3K27ac), and poised pro-
moters or enhancers (H3K4 methylation sometimes with
H3K27me3 but without H3K27ac)[49]. The histone
methylation profiles (Additional file 1: Table S2) also indi-
cate that two of the studied regions far downstream of
EGFR (1.35 kb downstream of the TSS in intron 1) and
SOX9 (2 kb downstream of TSS, in intron 2) have the
chromatin modifications typical of active promoters in
HMEC cultures, in which these genes are expressed.
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also very informative for the four intragenic or far-
upstream regions that displayed breast cancer-associated
DNA hypermethylation as well as a positive association
between DNA methylation and expression among TCGA
breast cancers (Additional file 1: Table S2). In HMEC cul-
tures, the examined EN1, PITX2 and LHX2 chromatin
regions all exhibited enrichment in H3K27me3. This his-
tone mark is often, but not always, associated with repres-
sion and frequently found in DNA regions in normal cells
(especially stem cells) that become hypermethylated dur-
ing carcinogenesis [50]. The pyrosequenced region in
APC, unlike the above three gene regions, exhibited the
histone marks of an active promoter (H3K4me3 and
H3K27ac) in HMEC. However, although this region is
30 kb downstream of the APC TSS defined by the isoform
NM_001127511, it overlaps an alternative promoter asso-
ciated with isoform NM_000038. Both isoforms encode
the APC protein, although their promoters are separated
by 30 kb, and both are functionally important [51]. HMEC
cultures express both isoforms abundantly, as indicated by
histone modification and RNA profiling in ENCODE da-
tabases (Additional file 1: Table S2). However, TCGA
methylation profiles showed that only the downstream
alternative promoter region becomes hypermethylated in
breast cancers. The average percent methylation at the
upstream and downstream promoters in invasive breast
cancer in the TCGA database were 10 and 28, respectively,
while those for paired normal tissue were 11 and 6.
Discussion
Using a candidate gene approach on a large, ethnically
diverse set of subjects, we compared not only invasive
breast cancer and adjacent histologically normal tissue
(as in the TCGA Illumina HumanMethylation450 data-
base [14]), but also control samples of reductive mam-
moplasty tissue from non-cancer patients using a
quantitative, gold-standard method for DNA methyla-
tion analysis (bisulfite/pyrosequencing) amenable to
archival FFPE samples. Our pyrosequencing analysis of
DNA methylation involved promoter DNA regions, re-
gions far upstream of genes, intragenic regions and
high-copy interspersed or tandem DNA repeats. In
addition, DNA methylation, transcriptome and histone
modification profiles from TCGA or ENCODE whole-
genome databases were used to enhance the analysis. A
limitation of our study of aberrant DNA methylation in
breast cancer is that clinical samples such as ours
include cell types other than breast epithelial cells.
Therefore, the methylation levels estimated in our study
represent an average across many cell types. Nonethe-
less, the similarities between hyper- or hypomethylation
determined in our bioinformatic comparisons of DNA
methylation in cancer-derived and normal mammaryepithelial cell cultures (Additional file 1: Tables S1 and S2)
and aberrant DNA methylation from our pyrosequencing
study of maligant and non-cancerous breast tissues
(Table 3) argue for our analysis indicating DNA changes,
at least in part, in the epithelial cell populations in cancers
vs. non-cancerous breast samples.
Besides confirming that a wide variety of DNA se-
quences display hyper- or hypomethylation in a large,
diverse collection of invasive breast cancers vs. adjacent
tissue, we demonstrated significant hyper- or hypome-
thylation in six of the 16 DNA regions examined in both
15 - 18 reduction mammoplasty samples and more than
100 histologically normal tissue samples adjacent to the
breast cancers. These six DNA sequences were in pro-
moter regions (RASSF1 and TFF1), an intron (EGFR), a
far-upstream (SGK1) gene regions or DNA repeats
(LINE-1 and Sat2). If control mammoplasty samples are
mimicking the epigenetics of normal breast tissue, then
our results suggest a field effect that could include
changes which predispose to carcinogenesis [12]. The
adjacent tissue samples used in our comparison had
been carefully evaluated morphologically and histologi-
cally for no evidence of malignancy. In addition, the lack
of evidence for a field effect for most of the studied
DNA regions, including for regions with frequent hyper-
methylation in the cancer tissue (e.g., RFX1 and EN1), is
consistent with a field effect rather than contamination
of adjacent samples with tumor tissue.
Field effects for DNA methylation changes in RASSF1,
EGFR and TFF1 might be important in influencing pre-
neoplastic changes in gene expression relevant to tumor
development. RASSF1 is a tumor suppressor gene that
regulates apoptotic and cell cycle checkpoints [52].
RASSF1 hypermethylation has been detected in carcin-
oma in situ and invasive breast cancer and is inversely
correlated with RNA and protein expression levels [24,
53, 54] and overall survival [55]. Like overexpression of
HER-2 protein, overexpression of EGFR protein, another
member of the epidermal growth factor/tyrosine kinase
family, is related to multiple drug resistance and
decreased patient survival [56, 57]. We demonstrated
significant hypermethylation of EGFR at part of the
extended promoter-like chromatin region (see below) in
intron 1 by comparing cancers with adjacent tissue.
Hypermethylation in this region was also seen in the
comparison of histologically normal, cancer-adjacent tis-
sue and control mammoplasty tissue. Given the proto-
oncogene status assigned to EGFR, it is not yet clear
what role hypermethylation of EGFR might play in
breast cancer progression.
Expression of TFF1, a gene encoding a small secretory
peptide implicated in preserving mucosa in the intestinal
track, is associated with promoter hypomethylation in
cultured cells and in breast cancers [29, 58]. We found
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inducible gene in both cancer vs. adjacent tissue and in
adjacent vs. control mammoplasty tissue. Expression of
TFF1 in breast cancer may be associated with a poor
outcome based upon breast cancer cell lines and a
mouse model [59]. However, a recent study of breast
cancer patients found that TFF1 expression was greater
for ER/PR positive breast cancers, which generally have
a better prognosis than ER/PR negative breast cancers
[60]. Similarly, we found that ER/PR positive tumors
showed greater hypomethylation compared with ER/PR
negative tumors.
One surprising result from our analysis was that the ex-
tended promoter region of BRCA1 did not show signifi-
cant hypermethylation in breast cancer relative to
adjacent tissue or control mammoplasty tissue despite the
fact that we chose a promoter region for analysis similar
to or overlapping those employed in other studies, many
of which did find BRCA1 hypermethylation in breast can-
cer [28, 31, 61–64]. The first three of these studies used
end-point methylation-specific PCR, which is extremely
sensitive for detection of any DNA methylation but is not
quantitative, and these studies reported only the percent-
ages of samples that were called as methylated. We found
very low average levels of methylation in the BRCA1 pro-
moter region in all samples (1.4, 1.6 and 3 % for control
mammoplasty, adjacent and cancer samples, respectively)
including a few outliers with considerable methylation. In
a study using MALDI-TOF mass array analysis of 48 FFPE
samples, only five of the 17 tested CpG sites displayed
hypermethylation in breast cancer vs. matching control
tissue, and the extent of hypermethylation at these five
sites was surprising high (averages of about 90 % for can-
cers vs. about 10 % for controls) [63]. However, as in our
study, MALDI-TOF [65] and methylation-specific multi-
plex ligation assays [64] by two other groups, each using
flash-frozen breast cancers and matching control tissue,
revealed only low percentages of cancers with greater
BRCA1 methylation compared with controls. Moreover, in
their studies and ours there was much more frequent can-
cer hypermethylation at many other tested promoter
regions. Similarly, bioinformatic analysis of methylation
levels in the HumanMethylation450 TCGA database
revealed insignificant differences between breast cancer
and adjacent tissue for the BRCA1 promoter region that
we examined (Table 5).
Our results from pyrosequencing that intronic
sequences far downstream of the canonical promoter
region (EGFR, LHX2, SOX9 and RFX1) and intergenic
sequences upstream of the promoter (PAX3 and EN1)
were significantly hypermethylated in breast cancer may
be related to new understandings of the transcription-
regulatory roles played by DNA methylation in intra-
genic and distant intergenic regions [2, 66]. For example,sequences considerably downstream of the TSS may be
part of the functional promoter or of transcription-
elongation regulatory elements such that local methyla-
tion could alter gene expression levels. This may be the
case for the pyrosequenced regions of EGFR (1.35 kb
downstream of the TSS in intron 1) and SOX9 (2 kb
downstream of TSS, in intron 2) far downstream of the
TSS. These two regions displayed hypermethylation in
cancer. In normal HMEC, where these two genes are
actively transcribed, ENCODE histone modification pro-
filing (Additional file 1: Table S2) indicates that the stud-
ied regions overlap large chromatin segments with
histone modifications typical of active promoters starting
in the canonical promoter region and continuing into
the 5’ intragenic region [13].
The importance of not restricting analysis of cancer-
linked aberrant DNA methylation to standard promoter
regions is also apparent from recent studies providing
evidence that DNA hypermethylation is implicated in
alternative promoter usage; regulating splicing of RNA;
and, in certain intragenic regions, in upregulating ex-
pression [2, 66]. Indeed, examples of the latter were seen
in our bioinformatic analyses of databases for DNA
methylation and expression in breast cancers (TCGA)
and in cultured cells (ENCODE). For example, we found
that DNA hypermethylation at APC was positively asso-
ciated with increased expression among breast cancers
(TCGA database). While the examined APC region is
30 kb downstream of the TSS in intron 1 of one APC
isoform expressed in HMEC, it is also in the promoter
region of another protein-coding isoform of the gene
transcribed in HMEC. Therefore, the cancer-associated
hypermethylation of this APC intron/promoter region
might help regulate levels of alternate promoter usage
for this gene.
The other three breast cancer-associated DNA hyper-
methylated regions which displayed significantly more ex-
pression in breast cancers with higher levels of DNA
methylation are 5.6 kb upstream of EN1, 7 kb upstream of
PITX2 or 4 kb downstream of the TSS of LHX2. These
genes code for homeobox-containing transcription factors
important in development. The location of these regions
and their association with normally repressive H3K27me3
in HMEC cultures (Additional file 1: Table S2) suggest
that the positive correlation of DNA methylation at these
regions with transcription may be due to their playing a
role in controlling the borders of active promoter regions
and counteracting the spread of H3K27me3-repressive
chromatin into the core promoter [67].
Conclusions
We identified frequent DNA methylation changes in in-
vasive breast cancer at a variety of genome locations and
found evidence for an extensive field effect in breast
Rauscher et al. BMC Cancer  (2015) 15:816 Page 14 of 15cancer. Empirical and bioinformatic analyses of these gene
regions provide further examples of the power of combin-
ing a candidate gene approach and bioinformatics using
publicly available databases to better understand the im-
portance of cancer epigenetic changes.
Additional file
Additional file 1: Table S1. “Promoter test region genes” and “Table
S2. Non-promoter test region genes”. Two tables containing sources of
and interpretation of DNA methylation, histone modification and expression
data for the selected genetic regions in the pyrosequencing study. Table
S1. describes regions found in gene promoter locations. Table S2.
describes regions found in intragenic or far-upstream regions to genes.
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